Despite weak analyst sentiment, this biotech is looking healthy for the new year.
Anavex Life Sciences Corp. (AVXL)
From The National Investor
I first recommended biotech researcher Anavex Life Sciences Corp. (AVXL) at the beginning of 2015. A combination of good news, an up listing to the full Nasdaq and a lot of excited press sent AVXL skyward in fairly short order; from under $1.00 to a bit over $14.00/share at the peak.
In the two-plus years since that peak, however, the company became the subject of brickbats among a few biotech-oriented bloggers. Whether too slow in clinical trials progress or whatever, sentiment has been sour on the company. Incredibly, it still is; and this despite its extremely encouraging quarterly report on December 11.
I was newly impressed on the call by the company’s C.E.O. and President Dr. Christopher Missling’s summation of things: “We are entering fiscal 2018 with our strongest balance sheet to date, which allows the company to carry out planned clinical studies for ANAVEX®2-73. This year has been an extraordinarily productive period for Anavex, with advanced preparation underway for studies in Rett syndrome, Alzheimer’s disease and Parkinson’s disease – all indications with high unmet need. . .”
While I can’t promise the explosive gains our Members enjoyed in 2015, Anavex—bouncing bouncing around the $3.25/share level—is newly compelling; and I just added it back to my recommendations as a BUY.
Chris Temple, The National Investor, www.nationalinvestor.com, 224-308-2587, January 4, 2017